Sugi Predict

Sugi Predict / Compounds / SCHEMBL279594

SCHEMBL279594

SCHEMBL279594

Cc1ccc2c(c1)NC(=O)CO2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MMP12 P39900 1/20 1.00
▸ PARP1 P09874 2/20 0.64
▸ BRD4 O60885 1/20 0.58
▸ CREBBP Q92793 1/20 0.58
▸ KDM4E B2RXH2 2/20 0.56
▸ NPC1 O15118 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ DRD2 P14416 2/20 0.55
▸ DRD4 P21917 2/20 0.55
▸ DRD3 P35462 1/20 0.55
▸ MAPT P10636 4/20 0.55
▸ POLB P06746 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ PKM P14618 4/20 0.52
▸ LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19188055 0.87 MMP12 (0.77) MMP12PARP1KDM4ENPC1RAB9A
SCHEMBL280003 0.86 MMP12 (0.75) MMP12PARP1KDM4ENPC1RAB9A
SCHEMBL4267366 0.83 MMP12 (0.70) MMP12PARP1KDM4ENPC1RAB9A
SCHEMBL4271023 0.83 MMP12 (0.70) MMP12PARP1RAB9AKMT2ADRD2
SCHEMBL13090978 0.83 MMP12 (0.71) MMP12PARP1BRD4CREBBPKDM4E
SCHEMBL13932083 0.80 MMP12 (0.65) MMP12PARP1BRD4CREBBPSMN1; SMN2
SCHEMBL20614334 0.80 MMP12 (0.65) MMP12PARP1SMN1; SMN2DRD2DRD4
SCHEMBL4272473 0.80 MMP12 (0.65) MMP12PARP1BRD4CREBBPSMN1; SMN2
SCHEMBL13932049 0.80 MMP12 (0.64) MMP12PARP1KDM4ENPC1RAB9A
SCHEMBL4261980 0.80 MMP12 (0.64) MMP12PARP1RAB9AKMT2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11932633-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2024-03-19 — — US disclosed
WO-2024020068-A1 BACTERIAL TOPOISOMERASE INHIBITORS OHIO STATE INNOVATION FOUNDATION (US) 2024-01-25 — — WO disclosed
US-20230365558-A1 TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF MEDSHINE DISCOVERY INC. (CN) 2023-11-16 — — US disclosed
US-20230339882-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2023-10-26 — — US disclosed
US-20230339882-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2023-10-26 — — US disclosed
EP-3458452-B1 HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION BUGWORKS RES INC (US) 2023-08-30 — — EP disclosed
EP-3573960-B1 N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES GENFIT (FR) 2023-08-16 — — EP disclosed
WO-2023101981-A1 SPIROCYCLIC INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-06-08 — — WO disclosed
WO-2023102140-A1 TMPRSS2 INHIBITORS AND METHODS OF USE TOPSPIN THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed
WO-2023102022-A1 4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-06-08 — — WO disclosed
EP-1173440-A1 TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-01-23 — — EP disclosed
WO-2000064899-A1 TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2000-11-02 — — WO disclosed
CN-1071427-A 6-Benzoxazinyl and 6-benzothiazine base-2,3,4,5-tetrahydro pyridazine-3-ketone ORTHO PHARMA CORP (US) 1993-04-28 — — CN disclosed
EP-0509845-A1 (+) and (-) enantiomers of 5-aliphatic-6-(benzoxazinyl- or benzothiazinyl)-2,3,4,5-tetrahydropyridazin-3-ones ORTHO PHARMACEUTICAL CORPORATION (US) 1992-10-21 — — EP disclosed
US-5081242-A Cardiotonic and bronchodilator agents; phosphodiesterase inhibitors ORTHO PHARMACEUTICAL CORPORATION (US) 1992-01-14 — — US disclosed
EP-0411751-A1 Renin inhibitory peptides Beecham Group p.l.c. (GB) 1991-02-06 — — EP disclosed
CN-87108354-A 6-benzoxazinyl and 6-benzothiazinyl-2, 3, 4, 5-tetrahydropyridazin-3-ones — 1988-09-21 — — CN disclosed
US-4766118-A CARDIOTONIC AGENTS, PHOSPHODIESTERASE INHIBITORS ORTHO PHARMACEUTICAL CORPORATION (US) 1988-08-23 — — US disclosed
EP-0272914-A2 6-Benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones ORTHO PHARMACEUTICAL CORPORATION (US) 1988-06-29 — — EP disclosed
US-4721784-A MUSCLE RELAXANTS, BRONCHODILATOR AGENTS, CARDIOTONIC AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1988-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365558-A1 TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF CYP3A7, UGT2B7, SFPQ MMP12 4524/4885PARP1 2720/4885BRD4 225/4885
US-20230339882-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF PTPRF, PTPRCAP, PTPRJ MMP12 609/4885PARP1 4201/4885BRD4 1628/4885
US-11932633-B2 KRas G12C inhibitors KRAS, NRAS, HRAS MMP12 1433/4885PARP1 1128/4885BRD4 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.